Finance

Lists
AVTX:NASDAQ
Avalo Therapeutics Inc
$18.64
+1.75%
(+0.32) 1D
Aug 10, 9:52:45 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AVTX...
Open
$18.25
High
$19.09
Low
$18.00
Mkt. cap
986.79M
Avg. vol.
1.31M
Volume
63.05K
52-wk high
$24.27
52-wk low
$8.29
EPS
-$5.83
Beta
0.80
Shares outstanding
53.63M
No. of employees
33
Open
$18.25
High
$19.09
Low
$18.00
Mkt. cap
986.79M
Avg. vol.
1.31M
Volume
63.05K
52-wk high
$24.27
52-wk low
$8.29
EPS
-$5.83
Beta
0.80
Shares outstanding
53.63M
No. of employees
33
About Avalo Therapeutics Inc
CEO-
Employees33
Founded2011
HeadquartersRockville, Pennsylvania, United States
SectorBiotechnology
Websiteavalotx.com
Analyst ratings
Based on 11 analysts giving stock ratings to AVTX in the past 3 months
Strong buy
Buy
11
Hold
0
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for AVTX in the last 3 months.
Highest
Current $18.64
$60.00 (+221.89%)
Average
$44.20 (+137.12%)
Lowest
$30.00 (+60.94%)
Analyst
Recommendation
Action
Price target
Projected
Date
Yatin Suneja
Guggenheim
Buy
Reiterated
$48.00
+157.5%
08/06/2026
Julian Harrison
BTIG
Buy
Maintained
$58.00
+211.2%
08/06/2026
Alec Stranahan
Bank of America Securities
Buy
Reiterated
$35.00
+87.8%
08/07/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$30.00
+60.9%
08/07/2026
Thomas Smith
Leerink Partners
Buy
Initiated
$38.00
+103.9%
07/06/2026
Stacy Ku
TD Cowen
Buy
Maintained
-
-
06/11/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$39.00
+109.2%
05/15/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$34.00
+82.4%
05/14/2026
Joseph Catanzaro
Mizuho Securities
Buy
Maintained
$45.00
+141.4%
05/14/2026
Jason Butler
Citizens JMP
Buy
Maintained
$55.00
+195.1%
05/14/2026
Yasmeen Rahimi
Piper Sandler
Buy
Reiterated
$60.00
+221.9%
05/11/2026
Andy Chen
Wolfe Research
Buy
Initiated
$48.00
+157.5%
04/08/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
59.00K
-
-
Cost of goods sold
9.99M
8.78M
10.15M
-
Cost of revenue
9.99M
8.78M
10.15M
-
Research and development expenses
3.63M
4.48M
3.90M
23.42M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.58M
6.53M
6.85M
8.10M
Operating expense
9.21M
11.02M
10.75M
31.52M
Total operating expenses
19.20M
19.80M
20.90M
31.52M
Operating income
-19.20M
-19.74M
-20.90M
-31.52M
Other non operating income
-12.53M
5.17M
480.00K
-7.58M
EBT including unusual items
-30.61M
-13.59M
-19.62M
-36.34M
EBT excluding unusual items
-30.61M
-13.59M
-19.62M
-36.34M
Income tax expense
11.00K
130.00K
12.00K
18.00K
Effective tax rate
-0.04%
-0.96%
-0.06%
-0.05%
Other operating expenses
-
-
-
-
Net income
-30.62M
-13.72M
-19.63M
-36.36M
Net profit margin
-
-23,254.24%
-
-
Earnings per share
-2.19
-0.37
-0.98
-0.83
Interest and investment income
1.12M
984.00K
803.00K
2.76M
Interest expense
-
-
-
-
Net interest expenses
1.12M
984.00K
803.00K
2.76M
Depreciation and amortization charges
-
-
-
-
EBITDA
-19.14M
-19.73M
-20.88M
-31.50M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps